| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | 0 | 12.795 | 11.504 | 14.157 | 15.568 | 17.348 | 16.707 | 24.088 | 29.992 |
| Total Income - EUR | - | 145 | 13.416 | 11.964 | 14.471 | 15.892 | 17.770 | 22.230 | 25.079 | 31.208 |
| Total Expenses - EUR | - | 1.966 | 12.146 | 13.911 | 26.616 | 13.555 | 15.749 | 21.727 | 23.827 | 26.713 |
| Gross Profit/Loss - EUR | - | -1.822 | 1.270 | -1.947 | -12.145 | 2.337 | 2.021 | 502 | 1.251 | 4.495 |
| Net Profit/Loss - EUR | - | -1.822 | 887 | -2.288 | -12.570 | 1.900 | 1.492 | -133 | 591 | 3.528 |
| Employees | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Noropharma Consulting Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | 0 | 0 | 0 | 11.475 | 8.443 | 6.027 | 4.616 | 4.137 | 1.525 |
| Current Assets | - | 40.538 | 40.892 | 36.700 | 12.496 | 16.037 | 19.352 | 21.165 | 17.340 | 21.578 |
| Inventories | - | 32.668 | 21.595 | 20.090 | 4.591 | 5.413 | 8.633 | 4.181 | 6.869 | 2.144 |
| Receivables | - | 223 | 5.140 | 2.421 | 2.955 | 2.146 | 804 | 662 | 1.404 | 550 |
| Cash | - | 7.647 | 14.156 | 14.189 | 4.950 | 8.479 | 9.915 | 16.322 | 9.066 | 18.884 |
| Shareholders Funds | - | 9.312 | 10.042 | 7.569 | -5.147 | -3.150 | -1.587 | -1.725 | -1.129 | 2.405 |
| Social Capital | - | 11.134 | 10.945 | 10.745 | 10.537 | 10.337 | 10.108 | 10.139 | 10.108 | 10.052 |
| Debts | - | 31.226 | 30.850 | 29.130 | 29.118 | 27.630 | 26.966 | 27.506 | 22.606 | 20.699 |
| Income in Advance | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4690 - 4690" | |||||||||
| CAEN Financial Year |
4690
|
|||||||||
Comments - Noropharma Consulting Srl